Thiourea Derivatives as Estrogen Receptor Alpha Inhibitors for Breast Cancer Therapy: An In Silico Evaluation with ADMET Prediction and Molecular Docking
Abstract
Breast cancer remains a significant public health challenge, necessitating the discovery of novel therapeutic agents. This study explores the potential of thiourea derivatives, specifically HU, HTMX, and BMPTU compounds, as estrogen receptor alpha (ERα) inhibitors using in silico approaches. Drug-likeness was assessed using Lipinski's Ro5, confirming good oral bioavailability for all compounds. ADMET analysis indicated favorable pharmacokinetic properties, with most derivatives demonstrating good intestinal solubility, minimal risks for metabolic interactions, and acceptable safety profiles, although BMPTU2 exhibited potential hepatotoxicity. Molecular docking studies revealed strong binding affinities for BMPTU derivatives, particularly BMPTU2, BMPTU3, and BMPTU4, which formed multiple hydrogen bonds and steric interactions with key ERα residues. These interactions suggest that BMPTU derivatives could function as ERα modulators, with further in silico and experimental validations needed to confirm their roles. Overall, the findings highlight BMPTU derivatives, especially BMPTU2, BMPTU3, and BMPTU4, as promising lead compounds for developing new breast cancer therapies targeting ERα. Further optimization and validation of these compounds are warranted to elucidate their therapeutic potential fully.
Full text article
References
Authors
Copyright (c) 2024 Hestining Puspaweni, Bambang Tri Purwanto, Tri Widiandani, Siswandono Siswodihardjo, M. Artabah Muchlisin
![Creative Commons License](http://i.creativecommons.org/l/by-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors continue to retain the copyright to the article if the article is published in the Borneo Journal of Pharmacy. They will also retain the publishing rights to the article without any restrictions.
Authors who publish in this journal agree to the following terms:
- Any article on the copyright is retained by the author(s).
- The author grants the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles (e.g., post-institutional repository) or publish them in a book, with acknowledgment of their initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process. This can lead to productive exchanges and earlier and greater citations of published work.
- The article and any associated published material are distributed under the Creative Commons Attribution-ShareAlike 4.0 International License.